These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 19632700)

  • 1. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
    Zolla-Pazner S; Cohen S; Pinter A; Krachmarov C; Wrin T; Wang S; Lu S
    Virology; 2009 Sep; 392(1):82-93. PubMed ID: 19632700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120.
    Chen H; Xu X; Lin HH; Chen SH; Forsman A; Aasa-Chapman M; Jones IM
    J Gen Virol; 2008 Oct; 89(Pt 10):2597-2604. PubMed ID: 18796729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.
    Narayan KM; Agrawal N; Du SX; Muranaka JE; Bauer K; Leaman DP; Phung P; Limoli K; Chen H; Boenig RI; Wrin T; Zwick MB; Whalen RG
    PLoS One; 2013; 8(1):e52732. PubMed ID: 23326351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.
    Eda Y; Takizawa M; Murakami T; Maeda H; Kimachi K; Yonemura H; Koyanagi S; Shiosaki K; Higuchi H; Makizumi K; Nakashima T; Osatomi K; Tokiyoshi S; Matsushita S; Yamamoto N; Honda M
    J Virol; 2006 Jun; 80(11):5552-62. PubMed ID: 16699036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    Binley JM; Wrin T; Korber B; Zwick MB; Wang M; Chappey C; Stiegler G; Kunert R; Zolla-Pazner S; Katinger H; Petropoulos CJ; Burton DR
    J Virol; 2004 Dec; 78(23):13232-52. PubMed ID: 15542675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.
    Zolla-Pazner S; Cohen SS; Boyd D; Kong XP; Seaman M; Nussenzweig M; Klein F; Overbaugh J; Totrov M
    J Virol; 2016 Jan; 90(2):636-49. PubMed ID: 26491157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.
    Zolla-Pazner S; Gorny MK; Nyambi PN; VanCott TC; Nádas A
    J Virol; 1999 May; 73(5):4042-51. PubMed ID: 10196300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein.
    Du SX; Xu L; Zhang W; Tang S; Boenig RI; Chen H; Mariano EB; Zwick MB; Parren PW; Burton DR; Wrin T; Petropoulos CJ; Ballantyne JA; Chambers M; Whalen RG
    PLoS One; 2011; 6(6):e20927. PubMed ID: 21738594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies.
    Calado R; Duarte J; Borrego P; Marcelino JM; Bártolo I; Martin F; Figueiredo I; Almeida S; Graça L; Vítor J; Aires da Silva F; Dias I; Carrapiço B; Taveira N
    Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32272637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen.
    Ou L; Kong WP; Chuang GY; Ghosh M; Gulla K; O'Dell S; Varriale J; Barefoot N; Changela A; Chao CW; Cheng C; Druz A; Kong R; McKee K; Rawi R; Sarfo EK; Schön A; Shaddeau A; Tsybovsky Y; Verardi R; Wang S; Wanninger TG; Xu K; Yang GJ; Zhang B; Zhang Y; Zhou T; ; Arnold FJ; Doria-Rose NA; Lei QP; Ryan ET; Vann WF; Mascola JR; Kwong PD
    Sci Rep; 2020 Feb; 10(1):3032. PubMed ID: 32080235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
    Rao PG; Lambert GS; Upadhyay C
    J Virol; 2023 Sep; 97(9):e0071023. PubMed ID: 37681958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities.
    Timofeeva A; Sedykh S; Nevinsky G
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.
    Balasubramanian P; Williams C; Shapiro MB; Sinangil F; Higgins K; Nádas A; Totrov M; Kong XP; Fiore-Gartland AJ; Haigwood NL; Zolla-Pazner S; Hioe CE
    Sci Rep; 2018 Jan; 8(1):542. PubMed ID: 29323175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.
    Balasubramanian P; Kumar R; Williams C; Itri V; Wang S; Lu S; Hessell AJ; Haigwood NL; Sinangil F; Higgins KW; Liu L; Li L; Nyambi P; Gorny MK; Totrov M; Nadas A; Kong XP; Zolla-Pazner S; Hioe CE
    Vaccine; 2017 Mar; 35(10):1464-1473. PubMed ID: 28185743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.
    Hessell AJ; McBurney S; Pandey S; Sutton W; Liu L; Li L; Totrov M; Zolla-Pazner S; Haigwood NL; Gorny MK
    Vaccine; 2016 May; 34(24):2713-21. PubMed ID: 27102818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.
    Kumar R; Pan R; Upadhyay C; Mayr L; Cohen S; Wang XH; Balasubramanian P; Nádas A; Seaman MS; Zolla-Pazner S; Gorny MK; Kong XP; Hioe CE
    J Virol; 2015 Sep; 89(17):9090-102. PubMed ID: 26109728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.
    Cardozo T; Wang S; Jiang X; Kong XP; Hioe C; Krachmarov C
    Vaccine; 2014 Sep; 32(39):4916-24. PubMed ID: 25045827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
    Andrabi R; Kumar R; Bala M; Nair A; Biswas A; Wig N; Kumar P; Pal R; Sinha S; Luthra K
    Virol J; 2012 Sep; 9():196. PubMed ID: 22971578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.
    Lin SC; Lin YF; Chong P; Wu SC
    PLoS One; 2012; 7(6):e39075. PubMed ID: 22720032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells.
    Jaworski JP; Krebs SJ; Trovato M; Kovarik DN; Brower Z; Sutton WF; Waagmeester G; Sartorius R; D'Apice L; Caivano A; Doria-Rose NA; Malherbe D; Montefiori DC; Barnett S; De Berardinis P; Haigwood NL
    PLoS One; 2012; 7(2):e31464. PubMed ID: 22359593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.